Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307 - Gralow, Julie R; Barlow, William E; Paterson, Alexander H G; M'iao, Jieling L; Lew, Danika L; Stopeck, Alison T; Hayes, Daniel F; Hershman, Dawn L; Schubert, Mark M; Clemons, Mark; Van Poznak, Catherine H; Dees, Elizabeth C; et al. (JNCI : Journal of the National Cancer Institute, 2020)
Keywords: Acids; Adjuvant therapy; Administration, Oral; Biomedical materials; Bisphosphonates; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone Neoplasms - prevention & control; Bone Neoplasms - secondary; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Chemotherapy, Adjuvant; Clinical trials; Clodronic acid; Clodronic Acid - administration & dosage; Clodronic Acid - adverse effects; Confidence intervals; Dental implants; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Disease-Free Survival; Estrogens; Female; Humans; Ibandronic acid; Ibandronic Acid - administration & dosage; Ibandronic Acid - adverse effects; Infusions, Intravenous; Intravenous administration; Jaw; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteonecrosis; Post-menopause; Rank tests; Statistical analysis; Statistical tests; Subgroups; Survival; Survival Rate; Toxicity; Treatment Outcome; Zoledronic acid; Zoledronic Acid - administration & dosage; Zoledronic Acid - adverse effects